pembrolizumab,lenvatinib
merck,eisai
['hcc', 'leap-002', 'up next']
up next at #esmo22: 3 (!) phase iii trials of systemic treatment in unresectable #hcc including leap-002 which has a 21 mo os for the interventional arm but was negative progress over the last 5 years in this disease is amazing, while at the same time many challenges remain 
MD - GI oncology @uzleuven @KU_Leuven